Bristol Myers Squibb Reports real-world evidence Data for Seladelpar in HIV-1 infection

Bristol Myers Squibb today announced real-world evidence results for Seladelpar in patients with HIV-1 infection. The study demonstrated that Seladelpar improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of HIV-1 infection and support the continued development of Seladelpar in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Seladelpar was consistent with previous observations, with no new safety signals identified.